Donor-specific Antibodies
Donor-specific Antibodies - Related Videos
04:43
COVID-19 Seroprevalence Test for IgG Antibody Levels Among Healthy Donors Across Different Pandemic Phases in Jeddah
0 Views •
2025
This study assessed COVID-19 seroprevalence in Jeddah, Saudi Arabia, among healthy blood donors across pre-lockdown, during-lockdown, and post-lockdown periods. Of 3,825 samples, 4.5% tested positive for IgG antibodies. Seroprevalence increased significantly post-lockdown, highlighting the role of asymptomatic transmission and the effectiveness of initial restrictions.
09:47
Analysis of Histone Antibody Specificity with Peptide Microarrays
0 Views •
Cited by 22 •
2017
This manuscript describes methods for applying peptide microarray technology to specificity profiling of antibodies that recognize histones and their post-translational modifications.
05:21
A Peptide Microarray Technology for Specificity Profiling of Antibodies
0 Views •
2025
This video demonstrates a technique that applies peptide microarray technology to profile the specificity of antibodies recognizing post-translational modifications (PTMs) on histone peptides. A microarray slide containing immobilized fluorophore-conjugated histone peptides with known PTM combinations is treated with target PTM-specific antibodies. This process helps identify the antibody's specificity for the target and its potential cross-reactivity with non-target PTMs.
04:13
A Technique to Assess the In Vivo Localization of Tumor-Specific Antibodies
0 Views •
2025
This video demonstrates a technique to study the in vivo localization of tumor-specific antibodies in a mouse tumor xenograft model. Upon subcutaneously injecting cancer cells into mice for tumor formation, fluorescently-labeled antibodies are injected that bind to tumor-specific receptors, enabling in vivo assessment of antibody localization via imaging.
02:53
A Technique to Generate Monoclonal Antibodies from Antigen-Specific B Cells
0 Views •
2025
The video demonstrates a technique for generating monoclonal antibodies from antigen-specific B cells. Eukaryotic expression vectors encoding the heavy and light chains of antibodies, cloned from isolated antigen-specific B cells, are introduced into mammalian cells using polyplexes. Once inside the cells, these vectors undergo translation, and the resulting heavy and light chain peptides assemble into antibodies, which are subsequently secreted by the cells.
FAQs
When these antibodies bind antigens on graft endothelial cells, they can activate complement and recruit other immune effector mechanisms. This combination can damage the transplant rather than merely signal immunologic mismatch. The resulting injury makes antibody detection clinically important because it supports assessment of compatibility and surveillance for antibody-mediated rejection after transplantation.
Donor-specific antibodies may exist before transplantation or arise afterward when recipient B cells respond to donor HLA. This timing distinguishes pre-existing immunologic risk from an antibody response that develops during follow-up. Measuring antibodies at relevant stages therefore helps clinicians interpret transplant risk and monitor whether the recipient is mounting a donor-directed response.
Human leukocyte antigens, or HLA, are the most common targets recognized by donor-specific antibodies. If recipient antibodies recognize donor HLA and attach to cells lining the graft’s blood vessels, they can initiate complement activation and immune-mediated injury. HLA-focused testing consequently provides a practical way to evaluate donor-recipient immunologic compatibility.
Antibody-screening and characterization tests identify donor-directed antibodies and help establish their target specificity, while a donor-recipient crossmatch evaluates the recipient’s immunologic reaction in relation to a particular donor. Together, these approaches connect general antibody findings with donor-specific compatibility information, supporting transplant risk assessment rather than relying on either result alone.
Laboratories first use antibody-screening approaches to detect relevant immunoglobulins, then characterize whether the antibodies recognize donor-associated targets such as HLA. A donor-recipient crossmatch adds a compatibility assessment involving the specific transplant pair. The combined results provide information for evaluating risk, supporting surveillance, and informing transplant management decisions.
Measurements are useful before transplantation for compatibility and risk assessment and after transplantation for surveillance of antibody-mediated rejection. In immunology and infection research, they also provide a way to study recipient immune responses directed toward transplanted tissue. Their value comes from linking antibody recognition with possible graft injury and subsequent management decisions.